We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PVP Procedure Based on Laser System

By HospiMedica staff writers
Posted on 29 Aug 2005
A new procedure for the treatment of benign prostatic hyperplasia (BPH) is based on a laser system. More...
The procedure has been approved for treating BPH in National Health Service (NHS) hospitals in England and Wales by the U.K. National Institute for Health and Clinical Excellence (NICE, London).

The procedure, called the photoselective vaporization of the prostate (PVP), was developed by Laserscope (San Jose, CA, USA). NICE approved the procedure after recent clinical studies showed excellent treatment results using the company's GreenLight PV laser system. In its review, NICE noted that the PVP procedure is satisfactorily safe, efficient, and effective for the treatment of BPH within the NHS system.

"Late last year, King's College in London was granted a prestigious award by the NHS for demonstrating the success of the PVP procedure on an outpatient basis, versus the more invasive trans-urethral resection of the prostate, or TURP, procedure,” noted Eric Reuter, president and CEO of LaserScope. "The award cited the hospital's ability to reduce costs and waiting times, while increasing patient satisfaction and experience through utilization of the PVP procedure.”

NICE is an independent organization formed in April 1999 to create a single excellence-in-practice body responsible for providing national guidance in the United Kingdom on the promotion of good health and the prevention and treatment of illness. NICE provides guidance to the NHS.

"Our number one priority has been to ensure that PVP using Laserscope's GreenLight PV laser system technology is recognized as the worldwide standard of care for treating BPH, and we believe we are getting closer and closer to achieving that goal every day,” added Mr. Reuter.




Related Links:
Laserscope >>

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.